ClinicalTrials.gg
TerminatedNCT04743804Updated Oct 1, 2024Results posted

Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger

A Phase 3 interventional study of Ravulizumab and Placebo in Thrombotic Microangiopathy, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 97 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Why this study was terminated
Recruitment Challenges

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Thrombotic Microangiopathies with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Thrombotic Microangiopathies · United States.

Enrollment
10th of 14
16 · median 24
Started
2021
with 3 others
Phase 3
7 of 20
none open now
Registered
14th of 20
by date
Lead sponsor
6 of 20
Alexion Pharmaceuticals, Inc.

Among the 20 studies in Thrombotic Microangiopathies with a site in United States, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 14th registered.

Thrombotic Microangiopathies

52 studies on the registry are indexed under Thrombotic Microangiopathies; 21 are open to participants now.

Browse Thrombotic Microangiopathies studies →

Open to participants now

3 of the 20 studies in Thrombotic Microangiopathies with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Thrombotic Microangiopathies studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Thrombotic Microangiopathies with a site in United States, or all of them as a file.
02

Study summary

This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. The treatment period is 26 weeks followed by a 26-week off-treatment follow-up period.

03

Conditions studied

  • Thrombotic Microangiopathy

Keywords

  • Complement
  • Trigger
  • Secondary thrombotic microangiopathy
  • Acute kidney injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. Body weight ≥ 30 kilograms
  3. Female participants of and male participants with female partners of childbearing potential must use highly effective starting at screening and continuing until at least 8 months after the last dose of ravulizumab
  4. TMA associated with a trigger ( disease, infection, solid organ transplant, drugs, and malignant hypertension)
  5. Vaccinated against meningococcal infection (Neisseria meningitidis), within 3 years prior to, or at the time of, randomization. Participants who initiate study drug treatment less than 2 weeks after receiving a meningococcal vaccine must receive appropriate prophylactic antibiotics for at least 2 weeks after the vaccination. If participant cannot receive the meningococcal vaccine, then participant must be willing to receive antibiotic prophylaxis coverage against N. meningitidis during the entire Treatment Period and for 8 months following the final dose of study drug. Additional vaccination (Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae) may be considered based on individual patient condition.

Exclusion criteria

Exclusion Criteria:

  1. Any known gene mutation that causes atypical hemolytic uremic syndrome (aHUS)
  2. Postpartum aHUS
  3. Known chronic kidney disease
  4. TMA due to hematopoietic stem cell transplantation ≤ 12 months of Screening
  5. Primary and secondary glomerular diseases other than lupus
  6. Diagnosis of primary antiphospholipid antibody syndrome
  7. Shiga toxin-producing Escherichia coli infections including but not limited to Shiga toxin-related hemolytic uremic syndrome
  8. Known familial or acquired 'a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13' (ADAMTS13) deficiency (activity \< 5%)
  9. Positive direct Coombs test which in the judgement of the Investigator is indicative of a immune-mediated hemolysis not due to TMA
  10. Clinical diagnosis of disseminated intravascular coagulation (DIC) in the judgement of the Investigator
  11. Presence of sepsis requiring vasopressors within 7 days prior to or during Screening
  12. Presence of monoclonal gammopathy including but not limited to multiple myeloma
  13. Known bone marrow insufficiency or failure evidenced by cytopenias
  14. Unresolved N. meningitidis infection
  15. History of within 5 years of Screening with the exception of nonmelanoma skin cancer or carcinoma in situ of the cervix that has been treated with no evidence of recurrence
  16. Use of any complement inhibitors within the past 3 years
  17. Respiratory failure requiring mechanical ventilation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Ravulizumab

    Biological: Ravulizumab · Other: Best Supportive Care

  • Placebo comparator
    Placebo

    Other: Placebo · Other: Best Supportive Care

Interventions

  • BiologicalRavulizumab

    Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.

    Also known as: Ultomiris, ALXN1210

  • OtherPlacebo

    Matching placebo

  • OtherBest Supportive Care

    Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26

    TMA response required the following: 1) Normalization of platelet count without transfusion support during the prior 7 days. 2) Normalization of LDH. 3) Improvement in glomerular filtration rate (eGFR) of \>= 30% compared to baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.

    Time frame: Week 26

Secondary outcomes

  1. Time to Complete TMA Response

    The Kaplan-Meier estimate of time to event of complete TMA response is reported. TMA response required the following: 1) Normalization of platelet count without transfusion support during the prior 7 days. 2) Normalization of LDH. 3) Improvement in eGFR of \>= 30% compared to baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. Participants who did not have a response were censored at the date of last visit or study discontinuation at the time when the analysis was performed.

    Time frame: Baseline through Week 26

  2. Number of Participants With Hematologic Response at Week 26

    Hematologic response required the following: (1) Normalization of platelet count without transfusion support during the prior 7 days, and (2) normalization of LDH.

    Time frame: Week 26

  3. Number of Participants With Renal Response at Week 26

    Renal response is improvement in eGFR of \>= 30% compared to baseline. If a participant is on dialysis ≤5 days prior to the date of eGFR assessment, the eGFR will be set to 10 milliliter/minute/1.73 meter square (mL/min/1.73 m\^2) for that assessment. If a participant is on dialysis during the entire 26 week randomized Treatment Period, or through early discontinuation of study drug, then the change in eGFR was not calculated.

    Time frame: Week 26

  4. Number of Participants On Dialysis at Week 26

    Time frame: Week 26

  5. Change From Baseline in eGFR at Week 26

    If a participant is on dialysis during the entire 26 week randomized Treatment Period, or through early discontinuation of study drug, then the change in eGFR was not calculated.

    Time frame: Baseline, Week 26

07

Results

Posted Dec 12, 2023
Limitations and caveats
Due to continued enrollment challenges, Alexion decided to terminate this study prematurely. There were no safety or efficacy concerns throughout the course of study. The planned interim analysis for sample size re-estimation and the planned primary analysis as specified in Protocol Amendment 2 were not conducted due to early termination of the study. No hypothesis testing or inferential statistical analysis for the purpose of treatment comparisons was performed due to small sample size.

Participant flow

Participant flow — Overall Study
MilestoneRavulizumabPlacebo
Started97
Received at least 1 dose of study drug97
Completed41
Not completed56
Withdrew: Other10
Withdrew: Withdrawal by subject01
Withdrew: Study terminated by sponsor14
Withdrew: Physician decision01
Withdrew: Death30

Outcome measures

PrimaryNumber of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26

TMA response required the following: 1) Normalization of platelet count without transfusion support during the prior 7 days. 2) Normalization of LDH. 3) Improvement in glomerular filtration rate (eGFR) of \>= 30% compared to baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26
ParticipantsRavulizumabPlacebo
Number of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 2623
SecondaryTime to Complete TMA Response

The Kaplan-Meier estimate of time to event of complete TMA response is reported. TMA response required the following: 1) Normalization of platelet count without transfusion support during the prior 7 days. 2) Normalization of LDH. 3) Improvement in eGFR of \>= 30% compared to baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. Participants who did not have a response were censored at the date of last visit or study discontinuation at the time when the analysis was performed.

Time frame:
Baseline through Week 26
Reported as:
Median · days
Time to Complete TMA Response
daysRavulizumabPlacebo
Time to Complete TMA ResponseNA (21.0 to NA)NA (16.0 to NA)
SecondaryNumber of Participants With Hematologic Response at Week 26

Hematologic response required the following: (1) Normalization of platelet count without transfusion support during the prior 7 days, and (2) normalization of LDH.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With Hematologic Response at Week 26
ParticipantsRavulizumabPlacebo
Number of Participants With Hematologic Response at Week 2656
SecondaryNumber of Participants With Renal Response at Week 26

Renal response is improvement in eGFR of \>= 30% compared to baseline. If a participant is on dialysis ≤5 days prior to the date of eGFR assessment, the eGFR will be set to 10 milliliter/minute/1.73 meter square (mL/min/1.73 m\^2) for that assessment. If a participant is on dialysis during the entire 26 week randomized Treatment Period, or through early discontinuation of study drug, then the change in eGFR was not calculated.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With Renal Response at Week 26
ParticipantsRavulizumabPlacebo
Number of Participants With Renal Response at Week 2644
SecondaryNumber of Participants On Dialysis at Week 26
Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants On Dialysis at Week 26
ParticipantsRavulizumabPlacebo
Number of Participants On Dialysis at Week 2610
SecondaryChange From Baseline in eGFR at Week 26

If a participant is on dialysis during the entire 26 week randomized Treatment Period, or through early discontinuation of study drug, then the change in eGFR was not calculated.

Time frame:
Baseline, Week 26
Reported as:
Mean · milliliter/minute/1.73 meter^2
Change From Baseline in eGFR at Week 26
milliliter/minute/1.73 meter^2RavulizumabPlacebo
Change From Baseline in eGFR at Week 2625.8 ± 19.9017.5 ± 7.59

Adverse events

Collected over Baseline up to Week 34. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ravulizumab3/9 (33.3%)6/9 (66.7%)9/9 (100%)
Placebo0/7 (0%)3/7 (42.9%)7/7 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventRavulizumabPlacebo
Escherichia urinary tract infectionInfections and infestations0/91/7
SepsisInfections and infestations0/91/7
Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/91/7
Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/91/7
Toxic epidermal necrolysisSkin and subcutaneous tissue disorders0/91/7
COVID-19 pneumoniaInfections and infestations1/90/7
Epstein-Barr viraemiaInfections and infestations1/90/7
PneumoniaInfections and infestations1/90/7
Urinary tract infectionInfections and infestations1/90/7
Ischaemic strokeNervous system disorders1/90/7
Most frequent other events
Showing 10 of 103
Most frequent other events
EventRavulizumabPlacebo
NauseaGastrointestinal disorders2/94/7
VomitingGastrointestinal disorders2/93/7
COVID-19Infections and infestations2/93/7
AnaemiaBlood and lymphatic system disorders3/90/7
DiarrhoeaGastrointestinal disorders1/92/7
PyrexiaGeneral disorders2/92/7
HypertensionVascular disorders2/92/7
DyspnoeaRespiratory, thoracic and mediastinal disorders2/92/7
Enterococcal infectionInfections and infestations2/90/7
PneumoniaInfections and infestations2/90/7

Baseline characteristics

The Modified Intent-to-Treat Analysis Set included all randomized participants, excluding participants who enrolled prior to availability of ST-HUS and ADAMTS13 central laboratory results and were subsequently found to be ineligible after randomization.

Age, Continuous
Age, Continuous(years)RavulizumabPlaceboTotal
Mean48.2 ± 15.7557.7 ± 17.7052.4 ± 16.77
Sex: Female, Male
Sex: Female, Male(Participants)RavulizumabPlaceboTotal
Female6410
Male336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RavulizumabPlaceboTotal
Hispanic or Latino235
Not Hispanic or Latino639
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RavulizumabPlaceboTotal
American Indian or Alaska Native000
Asian639
Native Hawaiian or Other Pacific Islander000
Black or African American000
White235
More than one race000
Unknown or Not Reported112
08

Study locations

97 sites
  • Research Site
    Tucson, Arizona 85724, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Gainesville, Florida 32610, United States
  • Research Site
    Lexington, Kentucky 40536, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Boston, Massachusetts 02118, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    Valhalla, New York 10595, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Columbus, Ohio 43203, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Salt Lake City, Utah 84115, United States
  • Research Site
    Morgantown, West Virginia 26505, United States
  • Research Site
    Belgium, 1200, Belgium
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liege, 4000, Belgium
  • Research Site
    Belo Horizonte, 30150-221, Brazil
  • Research Site
    Botucatu, 18618-687, Brazil
  • Research Site
    Campinas, 13083-894, Brazil
  • Research Site
    Fortaleza, 60430-375, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Ribeirão Preto, 14051-040, Brazil
  • Research Site
    Salvador, 41253-190, Brazil
  • Research Site
    Sao Paulo, 05403-000, Brazil
  • Research Site
    São Paulo, 04036-002, Brazil
  • Research Site
    Kingston, Ontario K7L 3N6, Canada
  • Research Site
    Toronto, Ontario M5B 1W8, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Quebec, G1R 3S1, Canada
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Chambéry Cedex, 73011, France
  • Research Site
    Lille, 59037, France
  • Research Site
    Montpellier, France
  • Research Site
    PARIS Cedex 12, 75571, France
  • Research Site
    Paris, 75020, France
  • Research Site
    Tours Cedex 09, 37044, France
  • Research Site
    Essen, 45147, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Bunkyo-ku, 113-8431, Japan
  • Research Site
    Iruma-Gun, 350-0495, Japan
  • Research Site
    Mitaka-shi, 181-8611, Japan
  • Research Site
    Miyazaki-shi, 889-1692, Japan
  • Research Site
    Nagoya-shi, 466-8560, Japan
  • Research Site
    Nagoya, 466-8650, Japan
  • Research Site
    Osaka, 565-0871, Japan
  • Research Site
    Sapporo-shi, 060-8648, Japan
  • Research Site
    Sendai-shi, 980-8574, Japan
  • Research Site
    Shinjuku-ku, 162-8666, Japan
  • Research Site
    Daegu, 42415, Korea, Republic of
  • Research Site
    Gwangju, 61469, Korea, Republic of
  • Research Site
    Seoul, 02841, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 04401, Korea, Republic of
  • Research Site
    Seoul, 06973, Korea, Republic of
  • Research Site
    Seoul, 134-727, Korea, Republic of
  • Research Site
    Seoul, 6591, Korea, Republic of
  • Research Site
    Amsterdam, 1100 DD, Netherlands
  • Research Site
    Groningen, 9713 GZ, Netherlands
  • Research Site
    Maastricht, 6229 HX, Netherlands
  • Research Site
    Nijmegen, 6500 HB, Netherlands
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Granada, 18014, Spain
  • Research Site
    Las Palmas de Gran Canaria, 35016, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Kaohsiung City, 833401, Taiwan
  • Research Site
    Kaohsiung, 81362, Taiwan
  • Research Site
    New Taipei, 23561, Taiwan
  • Research Site
    Taichung, 40447, Taiwan
  • Research Site
    Taichung, 40705, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Bristol, BS10 5NB, United Kingdom
  • Research Site
    Carshalton, SM5 1AA, United Kingdom
  • Research Site
    Exeter, EX2 5DW, United Kingdom
  • Research Site
    Leicester, LE3 9QP, United Kingdom
  • Research Site
    Liverpool, L7 8XP, United Kingdom
  • Research Site
    London, NW1 2BH, United Kingdom
  • Research Site
    London, NW3 2QG, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    London, SE5 9RS, United Kingdom
  • Research Site
    London, SW17 0QT, United Kingdom
  • Research Site
    Manchester, M13 9WL, United Kingdom
  • Research Site
    Newcastle-upon-Tyne, NE1 4LP, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
  • Research Site
    Oxford, OX3 9DU, United Kingdom
  • Research Site
    Salford, M6 8HD, United Kingdom
  • Research Site
    Stevenage, SG1 4AB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Dec 2022, 17 months.

Results were first posted in Dec 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2021
First posted
Feb 8, 2021
StartActual
Jun 29, 2021
Primary completionActual
Dec 22, 2022
CompletionActual
Dec 22, 2022
Results first posted
Dec 12, 2023
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04743804
Responsible party
Sponsor
First posted
Feb 8, 2021
Start date
Jun 29, 2021
Primary completion
Dec 22, 2022
Completion
Dec 22, 2022
Results posted
Dec 12, 2023
Last update
Oct 1, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion